Santhera Reports Results of Raxone (Idebenone) in P-III DELOS trial for Patients with Duchenne Muscular Dystrophy (DMD)

 Santhera Reports Results of Raxone (Idebenone) in P-III DELOS trial for Patients with Duchenne Muscular Dystrophy (DMD)

Santhera Reports Results of Raxone (Idebenone) in P-III DELOS trial for Patients with Duchenne Muscular Dystrophy (DMD)

Shots:

  • The P-III DELOS trial involves assessing of idebenone (900mg/day) vs PBO in 64 patients with DML for 52 wks.
  • P-III DELOS study results: 50% reduction in annual rates of forced vital capacity; treatment effect remained 6 yrs.; reduction in risk of important patient-relevant outcomes including bronchopulmonary AEs and hospitalizations; reductions in the rate of both inspiratory and expiratory respiratory function loss
  • Idebenone is a benzoquinone and a cofactor for the enzyme NAD(P)H H quinone oxidoreductase (NQO1) approved for Leber’s hereditary optic neuropathy (LHON) in the EU including n, Norway, Iceland, Liechtenstein, Israel and Serbia

Click here to read full press release/ article | Ref: Santhera Pharmaceuticals | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post